Table 4.
Overall adjusted vaccine effectiveness of PPV23 and estimates stratified by age at IPD, risk group and time since vaccination.
| Factor | Level | VE% (95% CI) | p-Value⁎ |
|---|---|---|---|
| All | – | 27 (17, 35) | |
| Age at IPD | 65–74 | 31 (16, 44) | 0.85 (0.22) |
| 75–84 | 17 (− 3, 32) | ||
| 85 + | 34 (17, 47) | ||
| Risk group | High risk immunocompetent | 25 (11, 37) | 0.050 |
| Immunocompromised | 13 (− 9, 30) | ||
| None | 45 (27, 59) | ||
| Time since vaccination | 0 to < 2 years | 41 (23 to 54) | 0.13 (0.23) |
| 2 to < 5 years | 34 (16 to 48) | ||
| ≥ 5 years | 23 (12 to 32) |
⁎
p-Value for difference in VE by strata and, in brackets the trend by age at IPD and time since vaccination.